Data and Commentary: The BANFF Study

• Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease

J Am Coll Cardiol. 2000;35:60-66.
Anderson TJ, Elstein E, Haber H, Charbonneau F.

With Commentary by
Todd J. Anderson, MD
Cardiology Division, Department of Medicine University of Calgary

The discovery of nitric oxide and other mediators released by the endothelium has opened up new strategies in treating cardiovascular disease. The clinical implication of these strategies focus on identifying therapies that can favorably modify vascular pathobiology.

An important step in this process is to fully characterize the effects of vasoactive agents on vascular endothelial function. The Brachial Artery Normalization of Forearm Function (BANFF) Study makes an important contribution to this topic, and we are pleased to include a reprint and accompanying commentary by the principal investigator, Todd J. Anderson, MD.

This CME program is offered by the University of Florida College of Medicine. It is part of a series of educational programs aimed at taking the mystery out of vascular biology and making it relevant to patient care.


Related at vwbg.org

Angiotensin-(1-7): New insights into the benefits of tissue ACE inhibition

Emerging new data are expanding our understanding of the renin-angiotensin system (RAS).

Angiotension type 1 receptor blockade versus ACE inhibition in the treatment of heart failure: Results of 3 clinical trials

Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.
More related